Advertisement

Cost-Utility Analysis of Mycophenolate Mofetil versus Methotrexate for Noninfectious Uveitis

Published:August 15, 2021DOI:https://doi.org/10.1016/j.oret.2021.08.004
      Immunosuppressive agents are used in the treatment of noninfectious uveitis.
      • Jabs D.A.
      • Rosenbaum J.T.
      • Foster C.S.
      • et al.
      Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.
      The First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, a multicenter, observer-masked, randomized trial, found no relative visual acuity differences in the effectiveness of methotrexate (MTX) and mycophenolate mofetil (MMF) as treatment for noninfectious intermediate, posterior, and panuveitis requiring corticosteroid-sparing therapy at 6 months.
      • Rathinam S.R.
      • Gonzales J.A.
      • Thundikandy R.
      • et al.
      Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial.
      This study examines the relative costs and cost-utility of MTX and MMF for noninfectious uveitis in adults.
      To read this article in full you will need to make a payment
      Subscribe to Ophthalmology Retina
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jabs D.A.
        • Rosenbaum J.T.
        • Foster C.S.
        • et al.
        Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.
        Am J Ophthalmol. 2000; 130: 492-513
        • Rathinam S.R.
        • Gonzales J.A.
        • Thundikandy R.
        • et al.
        Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial.
        JAMA. 2019; 322: 936-945
        • Brown G.C.
        Vision and quality-of-life.
        Trans Am Ophthalmol Soc. 1999; 97: 473-511
        • Jaffe G.J.
        • Dick A.D.
        • Brézin A.P.
        • et al.
        Adalimumab in patients with active noninfectious uveitis.
        N Engl J Med. 2016; 375: 932-943
        • Lin J.
        • Chang J.S.
        • Yannuzzi N.A.
        • Smiddy W.E.
        Cost evaluation of early vitrectomy versus panretinal photocoagulation and intravitreal ranibizumab for proliferative diabetic retinopathy.
        Ophthalmology. 2018; 125: 1393-1400
        • Neumann P.J.
        • Sanders G.D.
        • Russell L.B.
        • et al.
        Cost-Effectiveness in Health and Medicine.
        2nd ed. Oxford University Press, New York2017
        • Sugar E.A.
        • Holbrook J.T.
        • et al.
        • Multicenter Uveitis Steroid Treatment Trial Research Group
        Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.
        Ophthalmology. 2014; 121: 1855-1862